Neoadjuvant ipilimumab plus nivolumab in melanoma: 5-year survival and biomarker analysis from the phase 2 PRADO-trial [0.03%]
达拉菲尼联合曲美替尼治疗BRAF V600突变的转移性黑色素瘤：一项随机、双盲、III期临床试验（COMBI-v研究）的独立回顾分析
Lotte L Hoeijmakers,Petros Dimitriadis,Steven C M A Wijnen et al.
Lotte L Hoeijmakers et al.
Neoadjuvant ipilimumab plus nivolumab has become standard therapy for stage III melanoma based on the NADINA trial, although long-term data are lacking. In the phase 2 PRADO cohort of OpACIN-neo, 99 patients with stage III macroscopic melan...
Humoral IgG1 responses to tumor antigens underpin clinical outcomes in immune checkpoint blockade [0.03%]
针对肿瘤抗原的体液IgG1免疫反应影响免疫检查点阻断疗法的临床疗效
Edgar Gonzalez-Kozlova,Robert Sweeney,Igor Figueiredo et al.
Edgar Gonzalez-Kozlova et al.
Tumor-infiltrating T cells have been the primary focus of cancer immunotherapy; however, accumulating evidence points to a critical role for B cells and plasma cells in shaping responses to immune checkpoint blockade. In this study, we inve...
Student-led efforts promoting inclusivity and belonging in US medical schools [0.03%]
美国医学院校学生主导的包容性和归属感提升活动
Briana Macedo,Felipe Rosero Castro,Danielle Feffer et al.
Briana Macedo et al.
Professional medical associations as catalytic pathways for advancing women in academic medicine and promoting leadership [0.03%]
医学协会在促进女性学术医学发展和领导力方面的推动作用
Fawad A Khan,Margaret T Gopaul,Elizabeth J Howard et al.
Fawad A Khan et al.
Publisher Correction: Interpretable inflammation landscape of circulating immune cells [0.03%]
出版更正：循环免疫细胞可解释的炎症景观
Laura Jiménez-Gracia,Davide Maspero,Sergio Aguilar-Fernández et al.
Laura Jiménez-Gracia et al.
Published Erratum
Nature medicine. 2026 Jan 26. DOI:10.1038/s41591-026-04223-x 2026
Principles to guide clinical AI readiness and move from benchmarks to real-world evaluation [0.03%]
临床AI就绪原则及从基准评估到真实世界评价指南
Tej D Azad,Harlan M Krumholz,Suchi Saria
Tej D Azad
Richard Kitenge Omasumbu,Luca Fontana,Olivier le Polain de Waroux et al.
Richard Kitenge Omasumbu et al.
Nature Medicine Commission on dialysis policy in low- and middle-income countries [0.03%]
自然医学委员会：关于低收入和中等收入国家透析政策的报告
Yot Teerawattananon,Kinanti Khansa Chavarina,Jeerath Phannajit et al.
Yot Teerawattananon et al.
The global demand for kidney replacement therapy (KRT) continues to increase, yet access remains limited in many low- and middle-income countries. Thailand has been recognized for integrating a sustainable KRT delivery model into its Univer...